Compounds > N-(2-fluorophenyl)-2-[2-(4-thiazolyl)-1-benzimidazolyl]acetamide
Page last updated: 2024-12-09

N-(2-fluorophenyl)-2-[2-(4-thiazolyl)-1-benzimidazolyl]acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID1266440
CHEMBL ID393826
CHEBI ID117161

Synonyms (23)

Synonym
MLS-0067022.P001
smr000144389
MLS000538352
n-(2-fluorophenyl)-2-[2-(1,3-thiazol-4-yl)-1h-benzimidazol-1-yl]acetamide
CBKINASE1_010311
OPREA1_274240
CBKINASE1_022711
CHEBI:117161
n-(2-fluorophenyl)-2-(2-(thiazol-4-yl)-1h-benzo[d]imidazol-1-yl)acetamide
cid_1266440
bdbm50228096
CHEMBL393826 ,
BRD-K75606577-001-01-0
n-(2-fluorophenyl)-2-[2-(1,3-thiazol-4-yl)-1h-1,3-benzimidazol-1-yl]acetamide
mfcd02928023
AKOS001650325
HMS2460M12
n-(2-fluorophenyl)-2-[2-(1,3-thiazol-4-yl)benzimidazol-1-yl]acetamide
F0911-7068
n-(2-fluorophenyl)-2-[2-(4-thiazolyl)-1-benzimidazolyl]acetamide
Q27203791
SR-01000461884-1
sr-01000461884
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
TDP1 proteinHomo sapiens (human)Potency21.71230.000811.382244.6684AID686978; AID686979
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency39.81070.00419.962528.1838AID2675
Guanine nucleotide-binding protein GHomo sapiens (human)Potency5.62341.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
kallikrein-5 preproproteinHomo sapiens (human)IC50 (µMol)50.00001.359211.306050.0000AID1431
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
protein peptidyl-prolyl isomerizationPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
heart morphogenesisPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
protein foldingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
'de novo' protein foldingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
regulation of skeletal muscle contraction by regulation of release of sequestered calcium ionPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
protein maturation by protein foldingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
positive regulation of protein bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
regulation of protein localizationPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
negative regulation of activin receptor signaling pathwayPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
protein refoldingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
T cell activationPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
regulation of immune responsePeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
ventricular cardiac muscle tissue morphogenesisPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
regulation of ryanodine-sensitive calcium-release channel activityPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
heart trabecula formationPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
calcium ion transmembrane transportPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
supramolecular fiber organizationPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
regulation of amyloid precursor protein catabolic processPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
amyloid fibril formationPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
peptidyl-prolyl cis-trans isomerase activityPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
transforming growth factor beta receptor bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
protein bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
macrolide bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
FK506 bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
channel regulator activityPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
signaling receptor inhibitor activityPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
type I transforming growth factor beta receptor bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
transmembrane transporter bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
I-SMAD bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
activin receptor bindingPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
cytoplasmPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
cytosolPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
terminal cisternaPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
membranePeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
sarcoplasmic reticulumPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
Z discPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
cytoplasmic side of membranePeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
ryanodine receptor complexPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
sarcoplasmic reticulum membranePeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
cytoplasmPeptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID304388Induction of neurite outgrowth in Long-Evans rat E18/19 cortical neurons after 72 hrs2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors.
AID304387Binding affinity to human FKBP12 expressed in Escherichia coli BL21(DE3) by isothermal titration calorimetry2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.41 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thiabendazole
Tresaderm: dermatologic soln containing dexamethasone, thiabendazole & neomycin sulfate		2.03101,3-thiazoles;
benzimidazole fungicide;
benzimidazoles		antifungal agrochemical;
antinematodal drug
tacrolimus
Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.		2.0310macrolide lactambacterial metabolite;
immunosuppressive agent
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510